Literature DB >> 34244829

SAPS-3 performance for hospital mortality prediction in 30,571 patients with COVID-19 admitted to ICUs in Brazil.

Pedro Kurtz1,2,3, Leonardo S L Bastos4, Jorge I F Salluh1,5, Fernando A Bozza1,6, Marcio Soares7.   

Abstract

Entities:  

Year:  2021        PMID: 34244829      PMCID: PMC8270768          DOI: 10.1007/s00134-021-06474-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Dear editor, Severity of illness scores are used for benchmarking and assessment of adjusted mortality in intensive care units (ICU). The Acute Physiology and Chronic Health Evaluation (APACHE) and the Simplified Acute Physiology Score (SAPS) 3 scores were recently evaluated in ICU patients with coronavirus disease 2019 (COVID-19) with conflicting findings [1-4]. While in the cohorts from United Kingdom [1] and United States [2] ICU scores underestimated the actual mortality and poorly stratified disease severity, analyses from Austria using the SAPS-3 with first-level customization suggested satisfactory performance [3]. In this study, we aimed to evaluate the performance of SAPS-3 to predict hospital mortality in a large cohort of COVID-19 patients admitted to ICUs in Brazil. We included all adult patients (> 16 years) with RT-PCR-confirmed SARS-CoV-2 infection admitted to 188 ICUs of 45 hospitals (Rede D’Or São Luiz) from February 26th, 2020, to April 30th, 2021. Anonymized information was obtained from an electronic system, which contains prospectively collected structured data for all ICU admissions (Epimed Monitor®, Rio de Janeiro, Brazil). In addition to the standard equation (SE), we obtained recalibrated probabilities for COVID-19 patients after performing a first-level customization of the SAPS-3 equation (Supplementary Methods). We assessed the discrimination for hospital mortality using the area under the receiver operating curve (AUROC) and Brier’s Score with 95% confidence intervals (95% CI). Calibration was evaluated using the Hosmer–Lemeshow goodness-of-fit (GOF) test and the calibration belt method [5]. R 4.1 was used for all analyses. A total of 30,571 COVID-19 patients had complete hospital outcomes and were analyzed (Supplementary Table 1). Median age was 55 (interquartile range 42–69) years and 42% required advanced respiratory support. Overall, 4581 (15%) patients died in the hospital. Using the SAPS-3-SE, the predicted mortality was 15.7% and the standardized mortality ratio (SMR) was 0.95 (95% CI 0.93–0.98). Model`s discrimination was satisfactory (AUROC = 0.835 [95% CI 0.828–0.841]; Brier`s score = 0.097 [0.095–0.100]). However, the calibration was inappropriate for both SAPS-3-SE and the COVID-19-customized equation. Calibration belts and curves demonstrated underestimation of mortality in lower to intermediate risk groups and overestimation in higher risk group, which was unaffected by customization (Fig. 1; Supplementary sTable 2). These results were consistent when stratifying patients in three consecutive periods (Supplementary sTable 3 and sFigure 1).
Fig. 1

Calibration assessment of SAPS-3 standard equation and COVID-19 customized equation. Panel a calibration belts for predicted probabilities; Panel b calibration curves with predicted (blue line) and observed (red line) mortalities

Calibration assessment of SAPS-3 standard equation and COVID-19 customized equation. Panel a calibration belts for predicted probabilities; Panel b calibration curves with predicted (blue line) and observed (red line) mortalities We compared the main results of the present study with previous studies (Supplementary sTable 4). Our results did not confirm that first-level customization improves the performance of SAPS-3 in predicting hospital mortality in ICU patients with COVID-19 as shown by others. Differences in models’ performance may be caused by differing admission policies and the timing of patient ICU admission. Our study may also not reflect the entirety of the Brazilian healthcare system as we included data from a private healthcare network with almost unrestricted access to ICU care. Regardless, our findings reinforce that standard severity of illness scores should be used with caution for mortality prognostication or benchmarking of ICU performance in COVID-19 patients. Moreover, our results highlights the need for proper calibration of these scores to estimate risk-adjusted metrics such as the SMR in this population. Further work is warranted to improve current severity scores or develop COVID-19-specific prognostic measures. Below is the link to the electronic supplementary material. Supplementary file1 (PDF 809 KB)
  5 in total

1.  Coronavirus Disease 2019 ICU Patients Have Higher-Than-Expected Acute Physiology and Chronic Health Evaluation-Adjusted Mortality and Length of Stay Than Viral Pneumonia ICU Patients.

Authors:  Thomas L Higgins; Maureen M Stark; Kathy N Henson; Laura Freeseman-Freeman
Journal:  Crit Care Med       Date:  2021-07-01       Impact factor: 7.598

2.  Evaluation and calibration of SAPS 3 in patients with COVID-19 admitted to intensive care units.

Authors:  Philipp G H Metnitz; Rui P Moreno; Tobias Fellinger; Martin Posch; Paul Zajic
Journal:  Intensive Care Med       Date:  2021-05-19       Impact factor: 17.440

3.  Calibration belt for quality-of-care assessment based on dichotomous outcomes.

Authors:  Stefano Finazzi; Daniele Poole; Davide Luciani; Paola E Cogo; Guido Bertolini
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

4.  Acute Physiology and Chronic Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus Disease 2019.

Authors:  Xiaojing Zou; Shusheng Li; Minghao Fang; Ming Hu; Yi Bian; Jianmin Ling; Shanshan Yu; Liang Jing; Donghui Li; Jiao Huang
Journal:  Crit Care Med       Date:  2020-08       Impact factor: 7.598

5.  Analysis of Critical Care Severity of Illness Scoring Systems in Patients With Coronavirus Disease 2019: A Retrospective Analysis of Three U.K. ICUs.

Authors:  Jonny R Stephens; Richard Stümpfle; Parind Patel; Stephen Brett; Robert Broomhead; Behrad Baharlo; Sanooj Soni
Journal:  Crit Care Med       Date:  2021-01-01       Impact factor: 9.296

  5 in total
  5 in total

1.  Characteristics and outcomes of COVID-19 patients assisted by intensivists and nonintensivists.

Authors:  Sergio Henrique Loss; Deise Cappelletti Luce; Giovana Capellari
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-09       Impact factor: 1.712

2.  Prediction of in-hospital mortality: An adaptive severity-of-illness score for a tertiary ICU in South Africa.

Authors:  S Pazi; G Sharp; E van der Merwe
Journal:  South Afr J Crit Care       Date:  2022-05-06

3.  Critically ill COVID-19 patients in northeast Brazil: mortality predictors during the first and second waves including SAPS 3.

Authors:  Ana Paula Pires Lázaro; Polianna Lemos Moura Moreira Albuquerque; Gdayllon Cavalcante Meneses; Marza de Sousa Zaranza; Ana Beatriz Batista; Natalia Linhares Ponte Aragão; Andrea Mazza Beliero; Álvaro Rolim Guimarães; Nilcyeli Linhares Aragão; Alessandra Marjorye Maia Leitão; Marcelo Costa Freire de Carvalho; Maria Isabel de Alencar Cavalcante; Fabio Augusto Xerez Mota; Elizabeth De Francesco Daher; Alice Maria Costa Martins; Geraldo Bezerra da Silva Junior
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-05-22       Impact factor: 2.455

4.  Simplified Acute Physiology Score 3 Performance in Austrian COVID-19 Patients Admitted to Intensive Care Units with and without Diabetes.

Authors:  Faisal Aziz; Alexander Christian Reisinger; Felix Aberer; Caren Sourij; Norbert Tripolt; Jolanta M Siller-Matula; Dirk von-Lewinski; Philipp Eller; Susanne Kaser; Harald Sourij
Journal:  Viruses       Date:  2022-04-08       Impact factor: 5.048

5.  Leveraging a national cloud-based intensive care registry for COVID-19 surveillance, research and case-mix evaluation in Brazil.

Authors:  Amanda Quintairos; Ederlon Alves de Carvalho Rezende; Marcio Soares; Suzana Margareth Ajeje Lobo; Jorge Ibrain Figueira Salluh
Journal:  Rev Bras Ter Intensiva       Date:  2022 Apr-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.